Morgan Stanley Downgrades IMS Health (RX) to Underweight
More News related to RX
- Law Offices of Brian M. Felgoise, P.C. Announces Investigation on Behalf of Shareholders of IMS Health, Inc.
- Top 10 News Items 11/02-11/06: Unemployment Rate Now Over 10%, Fed to Keep Rates 'Exceptionally Low' for 'Extended Period', Buffett Does the Biggest Deal of His Life
- Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of IMS Health, Inc.
- Kendall Law Group Investigating IMS Health Inc. Takeover for Shareholders
- Holzer Holzer & Fistel, LLC Announces Investigation Into Purchase of IMS Health, Inc.
More News related to Downgrades
- RBC Capital Downgrades JA Solar (JASO) to Sector Perform
- Morgan Keegan Downgrades Zions Bancorporation (ZION) to Market Perform
- Hilliard Lyons Downgrades Humana (HUM) to Neutral
- Credit Suisse Downgrades Priceline.com (PCLN) to Neutral
- Citi Downgrades Allegheny Energy (AYE) to Hold
Morgan Stanley downgrades IMS Health (NYSE: RX) from Equalweight to Underweight. Price target $18.
IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
